CJ Godfrey, Ph.D.

Group Leader, Sr Principal Scientist I

CJ has 18 years of drug development experience in both pharma and consulting roles and has been applying pharmacometric methods to PK/PD/outcome analysis and decision support for 22 years. His clinical experience spans a broad range of biomarker, safety, and efficacy endpoints with particular emphasis on oncology, rare diseases, inflammation, and viral diseases. He has extensive experience in performing model-based meta-analyses and near-real-time population PK/PD modeling to support informed and timely decision making.

Recent publications by this scientist

Pharmacokinetic Modeling of Intrathecally Administered Recombinant Human Arylsulfatase A (TAK‐611) in Children With Metachromatic Leukodystrophy

June 1, 2020

Troy S, Wasilewski M, Beusmans J, Godfrey CJ.  Clin Pharmacol Ther. 2020 Jun;107(6):1394-1404. doi: 10.1002/cpt.1752. Epub 2020 Feb 25. PMID: 31868225; PMCID: PMC7325319.

View More

Pharmacokinetic & pharmacodynamic modeling and simulation of recombinant human arylsulfatase A in patients with metachromatic leukodystrophy: a preliminary evaluation

February 5, 2018

Troy S, Wasilewski M, Godfrey CJ. Poster presented at the 14th Annual WORLDSymposium. San Diego, CA. 5-9 February 2018.

Download PDF